- Introducing first-in-human therapies safely in small patient populations
- Balancing safety, efficacy and speed throughout development
- Using adaptive clinical trial designs where appropriate to accelerate development without compromising quality
- Working effectively with orphan drug pathways and regulators
- Practical lessons from rare disease clinical development programmes that delegates can apply within their own organisations
- Identifying high-risk protocol elements before finalisation
- Using site and investigator feedback before study start-up
- Balancing scientific ambition with operational feasibility
- Reducing rework through better cross-functional review
- Identifying where AI is already improving diagnosis
- Integrating AI into existing clinical workflows
- Overcoming implementation and governance challenges
- Measuring impact on referral pathways and patient outcomes
- Building inspection readiness into day-to-day trial management
- Demonstrating effective oversight throughout the study lifecycle
- Preparing documentation before inspectors ask for it
- Common findings and how sponsors could have prevented them
- Lessons learned from recent inspections
- The biggest opportunities changing rare disease development
- How sponsors can accelerate development without increasing operational risk
- Emerging regulatory and scientific priorities
- Where collaboration will matter most over the next five years
- Balancing scientific objectives alongside cost, timelines and recruitment potential
- Understanding how standards of care and comparator availability influence country selection
- Exploring opportunities in emerging regions while maintaining study quality
- Selecting countries that improve both operational delivery and scientific validity
